Core Viewpoint - ArriVent BioPharma, Inc. has announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $75 million to support its drug development programs and general corporate purposes [1][3]. Group 1: Offering Details - The public offering consists of 2,482,692 shares priced at $19.50 each and pre-funded warrants for 1,363,469 shares priced at $19.4999 each, with gross proceeds expected to be around $75 million before expenses [1]. - Underwriters have a 30-day option to purchase an additional 576,923 shares under the same terms [1]. - The offering is expected to close on or about July 3, 2025, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to support the development of firmonertinib and other pipeline programs, as well as for working capital and general corporate purposes [3]. Group 3: Company Background - ArriVent is a clinical-stage biopharmaceutical company focused on developing innovative therapies to meet unmet medical needs in cancer treatment [6]. - The company aims to leverage its team's extensive drug development experience to advance its lead candidate, firmonertinib, and a pipeline of novel therapeutics [6].
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants